Forsta AP Fonden Cuts Holdings in CVS Health Corporation $CVS

Forsta AP Fonden decreased its position in CVS Health Corporation (NYSE:CVS) by 2.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 259,900 shares of the pharmacy operator’s stock after selling 5,400 shares during the period. Forsta AP Fonden’s holdings in CVS Health were worth $17,928,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Jennison Associates LLC grew its stake in CVS Health by 503.8% in the 1st quarter. Jennison Associates LLC now owns 1,896,341 shares of the pharmacy operator’s stock valued at $128,477,000 after acquiring an additional 1,582,257 shares during the period. Cantor Fitzgerald Investment Advisors L.P. raised its position in shares of CVS Health by 1.6% during the 2nd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock valued at $28,264,000 after buying an additional 6,615 shares during the period. Brandywine Global Investment Management LLC lifted its stake in shares of CVS Health by 20.1% in the 1st quarter. Brandywine Global Investment Management LLC now owns 3,421,519 shares of the pharmacy operator’s stock valued at $231,808,000 after purchasing an additional 572,533 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in shares of CVS Health by 122.5% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 565,152 shares of the pharmacy operator’s stock valued at $38,289,000 after acquiring an additional 311,098 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of CVS Health by 1.4% in the first quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 708,479 shares of the pharmacy operator’s stock valued at $47,999,000 after buying an additional 9,634 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on CVS shares. Cantor Fitzgerald boosted their target price on CVS Health from $78.00 to $95.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Raymond James Financial lifted their target price on shares of CVS Health from $75.00 to $90.00 in a report on Friday, October 31st. The Goldman Sachs Group began coverage on shares of CVS Health in a report on Tuesday, October 14th. They set a “buy” rating and a $91.00 price objective on the stock. Bernstein Bank lowered their price target on shares of CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a research report on Wednesday, July 16th. Finally, Barclays raised their price target on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research note on Thursday, September 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.45.

CVS Health Trading Up 0.7%

Shares of CVS stock opened at $80.44 on Thursday. The firm has a market capitalization of $102.11 billion, a PE ratio of 211.69, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. The stock has a fifty day moving average of $77.50 and a two-hundred day moving average of $69.74. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $85.15.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. The company had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, research analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, October 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.3%. CVS Health’s dividend payout ratio (DPR) is presently 700.00%.

Insider Activity at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares of the company’s stock, valued at $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.